RAAS, ACE2 and COVID-19; a mechanistic review

The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in coronavirus disease 2019 (COVID-19) patients has been claimed as associated with the risk of COVID-19 infection and its subsequent morbidities and mortalities. These claims were resulting from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Elshafei, Ahmed, Khidr, Emad Gamil, El-Husseiny, Ahmed A., Gomaa, Maher H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270731/
https://www.ncbi.nlm.nih.gov/pubmed/34305426
http://dx.doi.org/10.1016/j.sjbs.2021.07.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270731/
https://www.ncbi.nlm.nih.gov/pubmed/34305426
http://dx.doi.org/10.1016/j.sjbs.2021.07.003

Ejemplares similares